Safety, efficacy, and PK/PD of a BCMA-targeted CAR-NK cell therapy (LUCAR-B68) in relapsed/refractory multiple myeloma: a phase I study. // Digital Chinese Medicine. – URL: https://www.sciencedirect.com/science/article/pii/S146532492600993X?dgcid=rss_sd_all
Safety, efficacy, and PK/PD of a BCMA-targeted CAR-NK cell therapy (LUCAR-B68) in relapsed/refractory multiple myeloma: a phase I study. Digital Chinese Medicine. https://www.sciencedirect.com/science/article/pii/S146532492600993X?dgcid=rss_sd_all
“Safety, efficacy, and PK/PD of a BCMA-targeted CAR-NK cell therapy (LUCAR-B68) in relapsed/refractory multiple myeloma: a phase I study.” Digital Chinese Medicine.
@article{article5297,
title = {Safety, efficacy, and PK/PD of a BCMA-targeted CAR-NK cell therapy (LUCAR-B68) in relapsed/refractory multiple myeloma: a phase I study},
journal = {Digital Chinese Medicine},
url = {https://www.sciencedirect.com/science/article/pii/S146532492600993X?dgcid=rss_sd_all}
}
Publication date: January 2027 Source: Cytotherapy, Volume 29, Issue 1 Author(s): Matic Bartol, Tina Fink, Tina Tragin, Ema Pleško, Roman Jerala, Hana Esih, Aljaž Kravanja, Brina Štante, Valentina Bianco, Luka Fajs, Mojca Jež